Chinese Startup Bochuang Biotech Initiates Human Clinical Trials for Collagen-Based Artificial Cornea E-Col

By Eye Future | 2026

In a conference room at Fudan University's Eye & ENT Hospital in Shanghai, a red banner hangs on the wall bearing the words: "Safety Study of Collagen-Reconstructed Corneal Microlenses for Refractive Error Correction — Kickoff Meeting." Behind it, nine people pose for a photo—the kind of moment that marks the transition from laboratory bench to human bedside.

This is where Bochuang Biotech, a Chinese startup founded in June 2022, has begun enrolling patients for clinical studies of its artificial corneal stroma product, E-Col. The move represents a milestone in China's third technological route for artificial corneas—one that builds the tissue from the ground up rather than repurposing what nature already made.

From Molecular Assembly to Medical Device

The cornea's transparency depends on collagen fibers arranged with nanometer-scale precision. Disrupt that order, and light scatters; vision clouds. For decades, researchers have tried to replicate this architecture, but the challenge isn't just having collagen—it's controlling how it assembles.

Bochuang Biotech's answer is a platform called Electrochemical Deposition of Biopolymers (EDP). According to public patents, the process involves custom-designed electrodes, EDP-guided collagen assembly, and chemical or photochemical crosslinking. The technique controls the assembly of Type I collagen molecules, forming microfibrils approximately 20 to 30 nanometers in diameter, then uses electric fields to pack them tightly together.

The team has designed template electrodes that match the curvature of the cornea, so the deposited E-Col emerges with an arc structure ready for implantation. The core technology traces back to Professor Liu Changsheng, an academician at East China University of Science and Technology, and Professor Qu Xue's team, which has worked on collagen-based medical materials since 2009, establishing a system for "physical field-precise control of collagen molecular assembly."

This approach differs fundamentally from decellularized animal corneas, which start with existing tissue and strip away cells. E-Col starts with raw collagen and builds upward—one modifies what's already there; the other constructs from scratch.

A Clear Development Path

Bochuang Biotech's timeline has been relatively disciplined. In 2023, the company conducted its first exploratory animal transplantation experiments. By late 2024, when it closed a Pre-A round led by Huafang Capital with participation from Taiyu Investment, Bangming Capital, and Lingjun Ventures, the product was still in preclinical animal evaluation.

In March 2026, the company announced a Pre-A+ round of over 10 million RMB (approximately 1.4 million USD), solely invested by Shanlan Capital. By then, E-Col had moved into clinical enrollment at Fudan University's Eye & ENT Hospital.

According to company disclosures, E-Col achieves light transmittance above 95%—a figure that approaches or exceeds some natural human corneas. Tensile strength and elastic modulus meet clinical implantation standards, and the design aims to reduce the risk of immune rejection and neovascularization.

Chairman Ren Dongni stated in the March 2026 funding announcement that the company's product has a cost advantage over imported brands and is expected to receive market approval within two years.

However, public records have not yet fully disclosed the study's sample size, design, primary endpoints, inclusion/exclusion criteria, specific indications, or follow-up period. These details will be critical for evaluating the product's clinical value.

Three Routes, Different Destinations

China's artificial cornea landscape is more fragmented than the term suggests. According to Xie Lixin, an academician of the Chinese Academy of Engineering, the country has approved four decellularized corneal stroma products and two domestic artificial cornea products, spanning three distinct technological routes.

The first uses decellularized animal corneal stroma—primarily porcine tissue processed to remove antigenic components while preserving the natural extracellular matrix structure. Youdeqing's product received approval in 2016, with Zhonghao Biotech and Yueqing Regenerative Medicine following. These products mainly serve lamellar keratoplasty and infectious corneal lesion repair.

The second route involves artificial material keratoprostheses. In December 2021, Beijing Mihe Medical's artificial cornea received NMPA Class III innovative medical device registration. Composed of PMMA optic pillars and titanium scaffold wings, it targets patients with bilateral corneal blindness for whom traditional keratoplasty has failed or is impossible—cases involving severe chemical burns, thermal burns, or autoimmune diseases. That same year, Guangdong Jiayue Meishi's keratoprosthesis also received registration.

The third route—collagen-based artificial corneal stroma—is where E-Col operates. Using purified collagen as raw material, it aims to create an integrable, remodelable implant that repairs or rebuilds the patient's own corneal stroma, rather than providing a permanent optical pathway.

These three categories serve different patient populations and clinical endpoints; direct comparison is inappropriate. E-Col’s competitive positioning will ultimately depend on its clinical indications and regulatory pathway. If positioned for lamellar keratoplasty, it will compete with decellularized corneal stroma; broader indications could allow it to address new clinical applications.

International Precedent: 24 Months of Human Data

Globally, collagen-based corneal tissue engineering has already entered human trials. In 2022, a team led by Linköping University in Sweden published research in Nature Biotechnology on BPCDX, a bioengineered corneal tissue made from medical-grade purified porcine Type I collagen, crosslinked through a dual process.

The researchers conducted studies in India and Iran, implanting BPCDX in 20 patients with advanced keratoconus and completing 24 months of follow-up. Results showed central corneal thickness increased by an average of 209±18 micrometers in Indian patients and 285±99 micrometers in Iranian patients. Maximum corneal curvature decreased by an average of 13.9±7.9D and 11.2±8.9D, respectively. Nineteen of the 20 subjects experienced vision improvement, all maintained corneal transparency, and no rejection, inflammation, or neovascularization events were observed.

These data demonstrate that collagen-based artificial corneal stroma can achieve long-term stability and safety in the human body.

However, BPCDX and E-Col differ in manufacturing. BPCDX uses porcine skin-derived Type I collagen and dual crosslinking, relying primarily on chemical crosslinks for structural stability. E-Col's core lies in electrochemical deposition controlling the directional alignment of collagen microfibrils, emphasizing fibril order at the molecular level. BPCDX data prove the concept that engineered collagen stroma can work in humans, but E-Col must build its own evidence chain through its own clinical studies.

What Comes Next

Once E-Col enters human clinical trials, the evaluation criteria shift. Whether the implant maintains long-term transparency, whether it integrates stably with the patient's own corneal tissue, whether material degradation matches tissue repair, and whether inflammation or neovascularization appears—these questions will determine the clinical value of this technological route.

Bochuang Biotech is also extending upstream into collagen raw materials, listing collagen and its derivatives as one of its main product directions. This vertical integration from raw material to implantable device offers supply chain and cost control logic in the collagen implant field.

But the transparency, tensile strength, and other parameters currently disclosed by E-Col come from company statements and have not yet been validated by peer-reviewed clinical research papers. Chairman Ren Dongni's statement that the product is "expected to receive market approval within two years" represents corporate expectation; actual approval timing depends on clinical trial progress and regulatory review processes. Key information about the human study's sample size, indication scope, and primary endpoint design remains undisclosed.

From basic research on controlling collagen alignment, to the construction of an electric field-regulated production line, to entry into human clinical trials, E-Col's technological route represents one of China's exploratory directions in regenerative medicine implants—moving away from reliance on decellularized natural tissue, instead attempting to "assemble" functional tissue at the molecular level.

Whether this path can succeed, and how far it can go, is a question clinical research will answer.

Source: Eye Future (眼未来) | Bochuang Biotech (江苏博创生物科技有限公司)